Browsing Category
Featured Articles
AstraZeneca’s Lokelma approved in Japan for the treatment of hyperkalaemia
AstraZeneca’s Lokelma (sodium zirconium cyclosilicate) has been approved in Japan for the treatment of patients with hyperkalaemia (elevated levels of potassium in the blood).
The…
Read More...
Read More...
Sorrento Launches Novel I-Cell COVID-19 Cellular Vaccine Program
Sorrento Therapeutics, Inc. announced it has been working on a novel decoy cellular vaccine for COVID-19 (STI-6991) and is in active discussions with the FDA’s Center for Biologics…
Read More...
Read More...
Merck Announces Top-Line Results from Phase 3 Trials Evaluating Gefapixant
Merck, known as MSD outside the United States and Canada, announced top-line efficacy results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and…
Read More...
Read More...
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced an update from the Phase III JAVELIN Head and Neck 100 study…
Read More...
Read More...
Thermo Fisher Scientific Signs Agreement with Janssen to Co-Develop Companion Diagnostic for Cancer
Thermo Fisher Scientific announced it has signed an agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to co-develop a companion…
Read More...
Read More...
FUJIFILM Diosynth Biotechnologies Breaks Ground On A New BioCampus At Its Billingham, UK Location
FUJIFILM Diosynth Biotechnologies (FDB), a world leading cGMP Contract Development and Manufacturing Organization (CDMO) supporting its partners in the biopharmaceutical industry with…
Read More...
Read More...
Gilead Initiates Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of…
Gilead Sciences announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 (novel coronavirus). These…
Read More...
Read More...
Sanofi to create new industry leading European company to provide API
Sanofi plans to create a major leading European company dedicated to the production and marketing to third parties of active pharmaceutical ingredients (API), which are the essential…
Read More...
Read More...
Comar to Expand West Coast Footprint
Comar, a specialty packaging, device, and component supplier serving the Medical, Pharmaceutical, Consumer Healthcare, Personal and Home Care, Food and Beverage, and other niche market…
Read More...
Read More...
Regeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New…
Regeneron Pharmaceuticals announced an expanded agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments combating the novel coronavirus,…
Read More...
Read More...
Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health Threat
Johnson & Johnson announced that it is mobilizing resources at its Janssen Pharmaceutical Companies to launch a multi-pronged response to the novel coronavirus (also known as…
Read More...
Read More...
Sandoz completes acquisition of Aspen’s Japanese operations
Sandoz announced that it has successfully completed the acquisition of the Japanese business of Aspen Global Incorporated (AGI), a wholly owned subsidiary of Aspen Pharmacare Holdings…
Read More...
Read More...
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the New Drug Application (NDA) for selpercatinib (LOXO-292), for the…
Read More...
Read More...
AbbVie and Allergan Announce Agreements to Divest Brazikumab and Zenpep
AbbVie and Allergan announced that Allergan has entered into definitive agreements to divest brazikumab (IL-23 inhibitor) and Zenpep (pancrelipase). These agreements are in conjunction…
Read More...
Read More...
BMS secures FDA priority review for NSCLC treatment combination
Bristol-Myers Squibb Company announced the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) in…
Read More...
Read More...
MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab
MorphoSys AG and Incyte Corporation announced that the companies have entered into a collaboration and license agreement to further develop and commercialize MorphoSys' proprietary…
Read More...
Read More...
Lilly Announces Agreement to Acquire Dermira
Eli Lilly and Company and Dermira, Inc. announced a definitive agreement for Lilly to acquire Dermira for $18.75 per share, or approximately $1.1 billion, in an all-cash transaction.…
Read More...
Read More...
FDA approves Fiasp for treatment of children with diabetes
Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) has approved Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with…
Read More...
Read More...
Merck Establishes Strategic Oncology Collaboration with Taiho and Astex
Merck, known as MSD outside the United States and Canada, announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., (“Taiho”) and…
Read More...
Read More...
Charles River Laboratories Completes the Acquisition of HemaCare Corporation
Charles River Laboratories International announced that it has completed the previously announced acquisition of HemaCare Corporation for approximately $380 million in cash, or $25.40…
Read More...
Read More...
